Diabetic Macular Edema
Conditions
Keywords
diebetic macular edema, optical coherence tomography, conbercept
Brief summary
Eyes with diabetic macular edema requiring conbercept treatment will be followed up for one month. Before treatment, one week after treatment and one month after treatment, the eyes will be examined by optical coherence tomography (OCT) and optical coherence tomographic angiography (OCTA). The changes of macular edema will be observed and analyzed by OCT leakage mapping software, and the relationship between the changes of macular edema and visual acuity will be analyzed.
Detailed description
1. Research purpose: After one month follow-up, we will observe whether OCTleakage mapping can be used as a biomarker to predict the prognosis of DME eyes, and will observe the effect of Conbercept on improving edema and visual acuity of DME eyes. 2. Subjects Number of subjects planned to be recruited: 35 Inclusion criteria: 1. Age ≥ 18 2. Diabetic macular edema eyes treated with conbercept for the first time in 1 week 3. Informed consent of patients and signing of informed consent Exclusion criteria: 1. High myopia 2. Macular diseases affecting vision 3. Vitreous hemorrhage requiring surgery 4. Patients with anterior segment neovascularization 5. Eye or periocular infection 6. Optic neuropathy and glaucoma 7. Periphlebitis, ophthalmic ischemic syndrome, uveitis, coat's disease, FEVR and other retinal diseases 8. Ametropia and cataract surgery 9. In 3 months, in addition to this treatment of conbercept, other anti VEGF treatment, laser treatment or vitreoretinal surgery were performed 10. Other systemic diseases can not complete follow-up
Interventions
None listed
Sponsors
Renmin Hospital of Wuhan University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1）Age ≥ 18 2\) Diabetic macular edema eyes treated with conbercept for the first time in 1 week 3\) Informed consent of patients and signing of informed consent
Exclusion criteria
1）Myopia ≥ 6.0D 2\) Macular diseases affecting vision 3\) Vitreous hemorrhage requiring surgery 4\) Patients with anterior segment neovascularization 5\) Eye or periocular infection 6\) Optic neuropathy and glaucoma 7\) Periphlebitis, ophthalmic ischemic syndrome, uveitis, coat's disease, FEVR and other retinal diseases 8\) Ametropia and cataract surgery 9\) In 3 months, in addition to this treatment of conbercept, other anti VEGF treatment, laser treatment or vitreoretinal surgery were performed 10\) Other systemic diseases can not complete follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| central retinal thickness（CRT） | 2020-12 | CRT will be measured by OCT software and the changes before treatment, 1 week after treatment and 1 month after treatment will be compared |
| best corrected visual acurity(BCVA) | 2020-12 | Compare the changes of BCVA before treatment, 1 week after treatment and 1 month after treatment |
| low optical ratio(LOR) | 2020-12 | The image will be processed by OCT leakage mapping software, and the changes of LOR will compared before treatment, 1 week after treatment and 1 month after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ellipsoid Zone | 2020-12 | The continuity of EZ will be judged by OCT image processing, and the changes before treatment, 1 week after treatment and 1 month after treatment will be compared |
Contacts
Primary ContactHongmei Zheng, MD
Backup ContactJingwen Jiang
Outcome results
None listed